The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
暂无分享,去创建一个
E. Sokol | K. Abhishek | S. Ganesan | S. Ou | V. Miller | G. Frampton | S. Millis | M. Gounder | S. Trabucco | Siraj M. Ali | C. Lovly | S. Soman | R. Madison | S. Pal | K. Janeway | P. Stephens | A. Schrock | L. Gay | L. Albacker | S. Paydaş | S. Klempner | U. Disel | Jon H. Chung | N. Karadurmuş | A. Benson | M. Ozturk | R. Cabanillas | V. Zhu | B. Wilky | Chaital I Nangia | J. Webster | V. Reddy | J. Ross | A. O. Matos
[1] S. Luoh,et al. Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial. , 2018 .
[2] E. Sokol,et al. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers , 2018, Clinical Cancer Research.
[3] Funda Meric-Bernstam,et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.
[4] Philip J. Stephens,et al. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal , 2018, PLoS Comput. Biol..
[5] R. Maki,et al. Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] B. Taylor,et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers , 2018, Nature.
[7] P. Stephens,et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.
[8] J. Blay,et al. Routine molecular screening of advanced refractory cancer patients: An analysis of the first 2490 patients of the ProfiLER study. , 2017 .
[9] P. Bradley. Adenoid cystic carcinoma evaluation and management: progress with optimism! , 2017, Current opinion in otolaryngology & head and neck surgery.
[10] C. Berking,et al. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] M. Berger,et al. The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform , 2017, JAMA oncology.
[12] C. Antonescu,et al. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] Alex M. Fichtenholtz,et al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. , 2016, Blood.
[14] P. Stephens,et al. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. , 2016, The oncologist.
[15] V. Miller,et al. Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.
[16] Jing Wang,et al. KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib , 2015, Clinical Cancer Research.
[17] I. Hwang,et al. Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). , 2015, The oncologist.
[18] Nicolas Servant,et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.
[19] J. Blay,et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. , 2015, The New England journal of medicine.
[20] Serkan Kurtgöz,et al. Amplification of Cellular Oncogenes in Solid Tumors , 2015, North American journal of medical sciences.
[21] Adam Kiezun,et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma , 2014, Proceedings of the National Academy of Sciences.
[22] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.
[23] Jeffrey A. Engelman,et al. Tyrosine kinase gene rearrangements in epithelial malignancies , 2013, Nature Reviews Cancer.
[24] A. D. Van den Abbeele,et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Levi A Garraway,et al. Precision oncology: an overview. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[27] Angela N. Brooks,et al. Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.
[28] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[29] K. Flaherty,et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] C. Antonescu,et al. KIT as a therapeutic target in metastatic melanoma. , 2011, JAMA.
[31] F. Heppner,et al. The 4q12 Amplicon in Malignant Peripheral Nerve Sheath Tumors: Consequences on Gene Expression and Implications for Sunitinib Treatment , 2010, PloS one.
[32] M. Stratton,et al. A census of amplified and overexpressed human cancer genes , 2010, Nature Reviews Cancer.
[33] M. Meyerson,et al. Amplification of chromosomal segment 4q12 in non-small cell lung cancer , 2009, Cancer biology & therapy.
[34] P. O'Connor,et al. Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 , 2008, Clinical Cancer Research.
[35] Andreas von Deimling,et al. Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme. , 2007, Neuro-oncology.
[36] L. Harris,et al. First-Line Herceptin® Monotherapy in Metastatic Breast Cancer , 2001, Oncology.
[37] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.